{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T08:02:49Z","timestamp":1775116969230,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaci-inpractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaip.2020.05.055","type":"journal-article","created":{"date-parts":[[2020,6,16]],"date-time":"2020-06-16T12:03:57Z","timestamp":1592309037000},"page":"3428-3433.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":32,"title":["Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization"],"prefix":"10.1016","volume":"8","author":[{"given":"Peter","family":"Wark","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sikandar","family":"Hussaini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl","family":"Holder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Oldmeadow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaip.2020.05.055_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/MCP.0000000000000129","article-title":"Allergic fungal airway disease: pathophysiologic and diagnostic considerations","volume":"21","author":"Woolnough","year":"2015","journal-title":"Curr Opin Pulm Med"},{"key":"10.1016\/j.jaip.2020.05.055_bib2","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/cea.12848","article-title":"The relationship between biomarkers of fungal allergy and lung damage in asthma","volume":"47","author":"Woolnough","year":"2017","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.05.055_bib3","doi-asserted-by":"crossref","first-page":"732","DOI":"10.3109\/02770903.2016.1154073","article-title":"Fungal sensitisation in severe asthma is associated with the identification of Aspergillus fumigatus in sputum","volume":"53","author":"Farrant","year":"2016","journal-title":"J\u00a0Asthma"},{"key":"10.1016\/j.jaip.2020.05.055_bib4","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/cea.12141","article-title":"Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria","volume":"43","author":"Agarwal","year":"2013","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.05.055_bib5","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1164\/rccm.201001-0087OC","article-title":"IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma","volume":"182","author":"Fairs","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.05.055_bib6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1398-9995.2010.02542.x","article-title":"Aspergillus sensitization is associated with airflow limitation and bronchiectasis in severe asthma","volume":"66","author":"Menzies","year":"2011","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.05.055_bib7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1164\/rccm.200805-737OC","article-title":"Randomized controlled trial of oral antifungal treatment for severe asthma with fungal sensitization: the Fungal Asthma Sensitization Trial (FAST) study","volume":"179","author":"Denning","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.05.055_bib8","series-title":"Xolair\u00ae omalizumab (rch) [product information]","year":"2017"},{"key":"10.1016\/j.jaip.2020.05.055_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1067\/mai.2003.49","article-title":"Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma","volume":"111","author":"Corren","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.05.055_bib10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jaip.2014.12.008","article-title":"Clinical efficacy and immunologic effects of omalizumab in allergic bronchopulmonary aspergillosis","volume":"3","author":"Voskamp","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaip.2020.05.055_bib11","first-page":"56","article-title":"Efficacy of omalizumab in severe asthma with fungal sensitisation: a case report","volume":"46","author":"Di Stefano","year":"2014","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.05.055_bib12","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jmii.2013.10.003","article-title":"Anti-IgE therapy for allergic bronchopulmonary aspergillosis","volume":"49","author":"Homma","year":"2016","journal-title":"J\u00a0Microbiol Immunol Infect"},{"key":"10.1016\/j.jaip.2020.05.055_bib13","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1002\/ppul.20907","article-title":"Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab)","volume":"43","author":"Kanu","year":"2008","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.jaip.2020.05.055_bib14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/thx.2004.035519","article-title":"Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody","volume":"62","author":"van der Ent","year":"2007","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2020.05.055_bib15","doi-asserted-by":"crossref","first-page":"A170","DOI":"10.1136\/thoraxjnl-2016-209333.303","article-title":"P160. Use of omalizumab in fungal allergic asthma","volume":"71","author":"Patel","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2020.05.055_bib16","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1111\/imj.13166","article-title":"Effectiveness and response predictors of omalizumab in a severe allergic asthma population with a high prevalence of comorbidities: the Australian Xolair Registry","volume":"46","author":"Gibson","year":"2016","journal-title":"Intern Med J"},{"key":"10.1016\/j.jaip.2020.05.055_bib17","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.05.055_bib18","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1136\/thoraxjnl-2017-210531","article-title":"Healthcare resource use and costs of severe, uncontrolled eosinophilic asthma in the UK general population","volume":"73","author":"Kerkhof","year":"2018","journal-title":"Thorax"},{"key":"10.1016\/j.jaip.2020.05.055_bib19","doi-asserted-by":"crossref","first-page":"1700765","DOI":"10.1183\/13993003.00765-2017","article-title":"\u201cI have lost in every facet of my life\u201d: the hidden burden of severe asthma","volume":"50","author":"Foster","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jaip.2020.05.055_bib20","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.jaip.2020.05.055_bib21","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1111\/j.1365-2222.2012.03981.x","article-title":"Exacerbations of severe asthma","volume":"42","author":"McDonald","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaip.2020.05.055_bib22","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.rmed.2013.12.012","article-title":"Anxiety, depression and personality traits in severe, prednisone-dependent asthma","volume":"108","author":"Amelink","year":"2014","journal-title":"Respir Med"},{"key":"10.1016\/j.jaip.2020.05.055_bib23","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.2217\/fmb.13.116","article-title":"Allergic bronchopulmonary aspergillosis in asthma: epidemiological, clinical and therapeutic issues","volume":"8","author":"Agarwal","year":"2013","journal-title":"Future Microbiol"},{"key":"10.1016\/j.jaip.2020.05.055_bib24","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1378\/chest.100.3.813","article-title":"Adjunctive therapy of allergic bronchopulmonary aspergillosis with itraconazole","volume":"100","author":"Denning","year":"1991","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2020.05.055_bib25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1067\/mai.2003.1388","article-title":"Anti-inflammatory effect of itraconazole in stable allergic bronchopulmonary aspergillosis: a randomized controlled trial","volume":"111","author":"Wark","year":"2003","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.jaip.2020.05.055_bib26","first-page":"CD003559","article-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaip.2020.05.055_bib27","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jaip.2020.05.055_bib28","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1378\/chest.12-1961","article-title":"A\u00a0proof-of-concept, randomized, controlled trial of omalizumab in patients with severe, difficult-to-control, nonatopic asthma","volume":"144","author":"Garcia","year":"2013","journal-title":"Chest"},{"key":"10.1016\/j.jaip.2020.05.055_bib29","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1398-9995.2004.00770.x","article-title":"The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma","volume":"60","author":"Bousquet","year":"2005","journal-title":"Allergy"},{"key":"10.1016\/j.jaip.2020.05.055_bib30","first-page":"PA659","article-title":"The ARIETTA study: baseline demographics in a real-world setting in patients with severe asthma","volume":"50","author":"Buhl","year":"2017","journal-title":"Eur Respir J"}],"container-title":["The Journal of Allergy and Clinical Immunology: In Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820305961?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213219820305961?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T05:28:18Z","timestamp":1761974898000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213219820305961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S2213219820305961"],"URL":"https:\/\/doi.org\/10.1016\/j.jaip.2020.05.055","relation":{},"ISSN":["2213-2198"],"issn-type":[{"value":"2213-2198","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Omalizumab Is an Effective Intervention in Severe Asthma with Fungal Sensitization","name":"articletitle","label":"Article Title"},{"value":"The Journal of Allergy and Clinical Immunology: In Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaip.2020.05.055","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}